Anktiva (nogapendekin)
Research Synopsis
Anktiva (nogapendekin)
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
London, UK
2 hours ago
1 Received
- * In the study, 71% of patients receiving NAI plus BCG achieved complete responses (CRs), with a median duration of over 26 months, suggesting that this combination is effective in prolonging patient remission and avoiding surgical procedures like cystectomy.
- * The results show a 55.4% disease-free survival rate at 12 months for a different subgroup treated with NAI plus BCG, while the majority of side effects were mild,
$100 - $150
Hourly Rate
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
London, UK
2 hours ago
1 Received
- - Despite promising results from immune checkpoint inhibitors, finding effective immunotherapies for solid tumors, like cancer, is still tough; however, Interleukin-15 (IL-15) shows potential by boosting immune cells like NK and CD8 lymphocytes.
- - Recombinant IL-15 (rIL-15) has issues with pharmacokinetics and safety, leading to the development of N803, a heterodimeric IL-15 agonist, which has demonstrated strong immune activation and safety in clinical trials.
- - N803, particularly when combined with nivolumab, has shown positive clinical responses in patients with non-small cell lung cancer and impressive results in bladder cancer patients resistant to BCG treatment, indicating its potential as
$100 - $150
Hourly Rate
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.
London, UK
2 hours ago
1 Received
- In the phase 2/3 QUILT-3.032 study, the combination of the IL-15RαFc superagonist N-803 and BCG effectively achieved durable complete responses in patients with nonmuscle-invasive bladder cancer that did not respond to BCG alone.
- Patient-reported outcomes were assessed through standardized questionnaires at multiple time points, revealing relatively stable scores in physical function and global health throughout the study period.
- The findings suggest that the treatment not only shows efficacy but also indicates a favorable risk-benefit ratio and maintained quality of life for the patients involved.
$100 - $150
Hourly Rate
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
London, UK
2 hours ago
1 Received
- The study focuses on overcoming the challenge of eradicating the viral reservoir to find a clinical cure for HIV-1 by using a combination of N-803 and broadly neutralizing antibodies (bNAbs) in rhesus macaques that were previously treated with antiretroviral therapy (ART).
- Researchers found that while the treatment induced some immune activation and transient viral levels, it did not significantly lower the viral reservoir. However, about 70% of treated macaques achieved sustained control of the virus after stopping ART.
- The success of viral control was linked to changes in CD8 T cells induced by the combination treatment, suggesting that eliminating the viral reservoir may not be necessary for long-term remission
$100 - $150
Hourly Rate
In brief: Anktiva for bladder cancer.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Nogapendekin alfa Inbakicept: First Approval.
London, UK
2 hours ago
1 Received
- Nogapendekin alfa inbakicept (ANKTIVA) is a new drug that combines recombinant interleukin-15 (IL-15) with a protein complex, designed to treat various cancers and HIV infection.* -
- In April 2024, it received approval for use alongside Bacillus Calmette-Guérin (BCG) specifically for adult patients with non-muscle invasive bladder cancer that doesn't respond to BCG treatment.* -
- The article details the key milestones in its development that led to this significant approval for cancer treatment.*
$100 - $150
Hourly Rate
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.
London, UK
2 hours ago
1 Received
- The summary discusses two studies evaluating the safety and efficacy of N-803 (Anktiva) combined with the standard treatment BCG for patients with non-muscle invasive bladder cancer (NMIBC).
- The Phase 1b study used increasing doses of N-803 in BCG-naive participants, while the Phase 2/3 study included participants with BCG-unresponsive disease and a cohort treated solely with N-803.
- Key findings showed that the combination treatment was effective, eliminating NMIBC in all nine BCG-naive participants and leading to long-lasting results, with a significant percentage of participants avoiding bladder surgery and experiencing minimal adverse effects.
$100 - $150
Hourly Rate
Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
London, UK
2 hours ago
1 Received
- There has been an increase in agents for treating bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC), and there is a pressing need for patient and therapy selection guidelines due to a lack of randomized trials.
- A global expert committee developed recommendations through literature reviews and a voting process, refining these guidelines during a live meeting in August 2023, achieving over 75% agreement on the final recommendations.
- No single optimal treatment exists for BCG-U patients; personalized treatment based on individual preferences, tumor characteristics, and available agent data is essential, with specific options recommended for carcinoma in situ and papillary-only tumors, and clinical trial participation encouraged.
$100 - $150
Hourly Rate
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.
London, UK
2 hours ago
1 Received
- High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) often requires treatment beyond Bacillus Calmette-Guérin (BCG) therapy due to high recurrence rates, with many patients needing radical cystectomy.
- Recent advancements include three FDA-approved biologics—Keytruda, Adstiladrin, and Anktiva—as well as promising gene therapies in clinical trials aimed at addressing this issue.
- The review highlights innovative drug delivery strategies, including targeted delivery and sustained release, to enhance therapeutic effectiveness and discusses ongoing research to improve future treatment options for NMIBC.
$100 - $150
Hourly Rate
Novel intravesical therapies and delivery systems for the management of bladder cancer.
London, UK
2 hours ago
1 Received
- Bladder cancer represents a significant health challenge globally, necessitating tailored treatment approaches for both non muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC).
- Recent advancements in intravesical therapies, like hyperthermic intravesical chemotherapy (HIVEC) and novel drugs, have shown promise in managing NMIBC and MIBC, although their long-term efficacy still needs further research.
- While innovative treatments such as hydrogels and drug-releasing systems (drug-RIS) appear safe and effective, careful patient selection is crucial, as radical cystectomy remains the primary treatment option for bladder cancer.
$100 - $150
Hourly Rate